While it makes complete sense that we are all searching for something...anything...to get rid of our melanoma and/or make our treatments more effective...even "benign" "natural" supplements can cause problems!!! I published this in 2016: Combining alternative and conventional treatments for melanoma....a risky business!
Now, there's this:
The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. Knapen, Koornstra, Driessen, et al. Target Oncol. 2018 Apr 11.
The
impact of dose and simultaneous use of acid-reducing agents (ARAs) on
the effectiveness of vemurafenib is unknown.
To
determine the association between progression of metastatic BRAF V600
mutated melanoma and (1) dose reductions of vemurafenib and (2)
simultaneous use of vemurafenib and ARAs.
A
retrospective cohort study of 112 first-line vemurafenib users for
melanoma was conducted (March 2012-March 2016), using electronic
patient records and pharmacy dispensing records of a Dutch academic
hospital. Cox regression analysis was used to estimate the risk of
progression with full-dose (n = 64) versus reduced-dose
vemurafenib (n = 48) and with simultaneous use of vemurafenib and
ARAs (n = 35) versus vemurafenib alone (n = 77). Analyses
were adjusted for age and sex.
In
total, disease progression occurred in 55% of treated patients on
vemurafenib, with a median progression-free survival of 6.0 months. Compared to patients on
vemurafenib alone, there was no increased risk of progression among
patients requiring vemurafenib at a reduced dose or among patients
receiving simultaneous therapy with vemurafenib and ARAs. In
addition, there was no increased risk of progression among patients
who used reduced-dose vemurafenib and ARAs versus those receiving
full-dose vemurafenib as sole therapy. However, a tendency for
progression was observed among patients who used full-dose
vemurafenib and ARAs versus full-dose vemurafenib alone, which became
statistically significant in a sensitivity analysis.
While this is not the most definitive study...these data certainly point to the need for caution when adding "complementary" treatments to your melanoma therapy!!! Stay well! - c
No comments:
Post a Comment